What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025BloodOpen Access

Tailored prophylaxis in severe hemophilia A: Real-world experience with efanesoctocog alfa

View Full Paper

Ask AI

Bookmark

Clinical outcomes improved with efanesoctocog alfa, achieving zero annualized bleeding rate in severe hemophilia A cases.
Both patients transitioned to efanesoctocog alfa experienced enhanced quality of life as assessed by Hema-A QoL.
Pharmacokinetic profiling indicated increased FVIII activity and reduced treatment burden with once weekly dosing.
Personalized treatment strategies using PK evaluations support effective management of severe hemophilia A.

No takes yet. Share an insight, caveat, or question.

Observational analysis shows improved clinical outcomes in severe hemophilia A with efanesoctocog alfa, indicating enhanced treatment efficacy.

Gameil et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis shows improved clinical outcomes in severe hemophilia A with efanesoctocog alfa, indicating enhanced treatment efficacy.